Advanced Cancer Clinical Trial
— ICCSOfficial title:
Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses
Verified date | September 2014 |
Source | University of Washington |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
This research study is a randomized trial to evaluate a training program that is designed to improve the communication skills of clinicians. The training program focuses on care for patients with serious illnesses and their family members, and assesses effectiveness using patient and family outcomes. The long term goal of this research is to improve communication skills of doctors and nurses, thereby improving patient and family outcomes.
Status | Completed |
Enrollment | 6086 |
Est. completion date | March 2013 |
Est. primary completion date | February 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Physician: - all internal medicine residents at either University of Washington (UW)or the Medical University of South Carolina - who have a clinical rotation allowing implementation of the intervention. NP Student: - All NP Students at UW or MUSC - in programs that train them to work with the following patient types: - Adult patents with Cancer or other chronic, life-limiting illnesses - Older Adults - Adults Primary Care Patients Patient: One or more of the following diagnostic criteria: - Advanced Cancer; - Chronic obstructive pulmonary disease (COPD) with FEV1 values < 35% predicted and/or oxygen dependent; - Restrictive lung disease with a TLC < 50% predicted; - Congestive heart failure with an ejection fraction <30% or functional deficits matching New York Heart Association Class III or IV heart failure; - End stage liver disease including Child's Class C cirrhosis, MELD score = 18, a variceal bleed, refractory ascites, or spontaneous bacterial peritonitis (SBP); - a Charlson Comorbidity Score point value =6; - in-patients with a University HealthSystem Consortium (UHC) Risk of Mortality score of major or extreme; - OR hospitalized patients = 80 years. Family: - The ability to speak English well enough to be able to complete the study procedures - AND no significant dementia or delirium that would limit the family member's ability to complete instruments. Nurse-evaluators: - are working in the hospital or clinic with the resident or NP student enrolled in the study. Exclusion Criteria: - less than 18 years, - significant dementia, delirium, or psychosis; - the inability to speak English well enough to be able to complete the study procedures. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | University of Washington; Harborview Medical Center | Seattle | Washington |
United States | University of Washington; UW Medical Center | Seattle | Washington |
United States | Veteran's Affairs Puget Sound HCS | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Washington | National Institute of Nursing Research (NINR) |
United States,
Curtis JR, Back AL, Ford DW, Downey L, Shannon SE, Doorenbos AZ, Kross EK, Reinke LF, Feemster LC, Edlund B, Arnold RW, O'Connor K, Engelberg RA. Effect of communication skills training for residents and nurse practitioners on quality of communication wit — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient and family ratings on the "End-of-Life domain" of the Quality of Communication Questionaire (QOC) | 4/1/2007-3/31/2012 | No | |
Secondary | Patient symptoms of depression as assessed by the PHQ-8 (Memorial Symptom Assessment scale) | 4/01/2007-3/31/2012 | No | |
Secondary | Patient-, family-, and nurse-assessed ratings of the quality of end-of-life care provided by study clinicians using Quality of End-of-Life Care questionaire | 4/01/2007-3/31/2012 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01901237 -
Yoga for Adolescent and Young Adult Non-Curative Cancer Patients
|
N/A |